AMGN Declares A Head-to-Head Phase III; CNAT Reports Acceptance Of Abstract For AASLD Meeting
October 09, 2014 at 10:56 AM EDT
Amgen (AMGN) has claimed gaining regulatory approval for its biosimilar of Humira, AbbVie's (ABBV) mega blockbuster anti-inflammatory drug.
